Organization
Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan
3 abstracts
Abstract
Prognosis of locoregional recurrence after early breast cancer with immediate breast reconstruction.Org: Department of Breast Surgery, Kyorin University School of Medicine/Saitama Medical Center, Tokyo, Japan, Department of Breast Surgery, Japanese Red Cross Medical Center/Department of Breast Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan, Department of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kanagawa, Japan, Yokohama City University Medical Center, Yokohama, Japan,
Abstract
Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan, St. Luke's International Hospital, MD Anderson Cancer Center, Department of Thoracic and Head and Neck Medical Oncology,
Abstract
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.Org: Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, Core Laboratory, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, Department of Breast and Endocrine Surgery, Akita University Hospital, Akita, Japan,